B-cell based gene therapy for inducing tolerance

Indira Carey, Yan Su, Yufei Jiang, Jonathan Skupsky, David W. Scott*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


The ability of B cells to function as tolerogenic antigen presenting cells (APCs) in vitro and in vivo, makes them ideal targets for gene therapy strategies focused on the induction and re-establishment of tolerance. Current therapy methods employ retroviral vectors for infection of B cells or bone marrow cells and subsequent expressionol the target antigen. Moreover, the efficacy of peptide-IgG fusion constructs which take advantage of the tolerogenic properties of IgG has been demonstrated. In this review, we discuss gene therapy approaches mediated by B cells and bone marrow cells for tolerance acquisition in various mouse models for autoimmune disease, hemophilia and transplantation. The results indicate that gene therapy strategies successfully reduce the incidence of disease, or delay disease onset in multiple mouse models for autoimmune disease and hemophilia. Additionally, gene therapy has proven effective in a mouse transplantation model. While these studies show great promise, the mechanisms involved in tolerance, including the role of regulatory T cells, will need to be more clearly defined before the transition to a clinical setting can occur.

Original languageEnglish
Pages (from-to)141-150
Number of pages10
JournalAnti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry
Issue number2
StatePublished - May 2007
Externally publishedYes


  • Antigen presentation
  • Autoimmunity
  • B cells
  • Bone marrow cells
  • Gene therapy
  • Hemophilia
  • Immunoglobulin fusions
  • Retroviral vector
  • Tolerance
  • Transplantation


Dive into the research topics of 'B-cell based gene therapy for inducing tolerance'. Together they form a unique fingerprint.

Cite this